MRD Negativity in Focus: Dr. Usmani on New CARTITUDE-4 Data

Saad Z. Usmani, MD, MBA, FACP, FASCO of Memorial Sloan Kettering Cancer Center provides a detailed recap of the CARTITUDE-4 clinical trial data, which compared ciltacabtagene autoleucel to standard-of-care treatments in lenalidomide-refractory patients with multiple myeloma. Based on a presentation from the 66th American Society of Hematology Annual Meeting & Exposition, which focused on the MRD-negative population of CARTITUDE-4, Usmani offers insights into the latest findings and their potential to reshape treatment strategies.